Educational Symposium
Hepatorenal Syndrome Type 1: Diagnosis Methods and Management
October 23, 2020 | 01:00 PM - 02:00 PM
Location: Simulive
Session Description
Hepatorenal syndrome (HRS) type 1 is an AKI characterized by rapid and progressive loss of kidney function in patients with liver disease. AKI is common in patients with advanced liver disease, and HRS is a diagnosis of exclusion.
Because AKI among patients with liver disease can have a variety of causes, the diagnosis of HRS is often difficult to make, which has important ramifications from a prognostic and therapeutic standpoint. Indeed, a diagnosis of HRS type 1 implies a very high morbidity and mortality, which can lead to premature decision-making about therapy. Clinical research is currently exploring more accurate methods for establishing a diagnosis of HRS. This symposium provides an update on the tests used to diagnose and classify AKI in cirrhosis and HRS.
Treating AKI in liver disease includes the treatment of volume depletion (typically with albumin), abdominal compartment syndrome (if present), and associated infections, as well as the use of vasopressors and RRT. With the exception of reversible acute liver injury, the definitive treatment of HRS is liver transplantation.
Support is provided by an educational grant from Mallinckrodt LLC.
Learning Objective(s)
- Describe the diagnostic methodology for HRS and differentiate it from AKI in liver cirrhosis
- Discuss the therapeutic approach to HRS type 1
Learning Pathway(s)
- Acute Kidney Injury
Moderator
- Chirag R. Parikh, MD, PhD, FASN
Presentations
- Introduction
01:00 PM - 01:10 PM
Chirag R. Parikh, MD, PhD, FASN
- Diagnostic Methods and Classification of AKI in Cirrhosis: Establishing HRS Type 1
01:10 PM - 01:35 PM
Justin Miles Belcher, MD, PhD
- Therapeutic Approach for Patients with HRS Type 1
01:35 PM - 02:00 PM
Andrew S. Allegretti, MD, MS